Premature Ovarian Insufficiency (POI): Causes, Diagnosis and Fertility Options

Premature Ovarian Insufficiency (POI): A Complete Guide

Premature ovarian insufficiency (POI) is diagnosed when the ovaries stop functioning normally before age 40. It affects approximately 1–2% of women. Despite often being called "premature menopause," POI is distinctly different — and understanding the difference matters for treatment and fertility planning.

POI vs Premature Menopause: What Is the Difference?

Premature menopause implies permanent, irreversible cessation of ovarian function before 40.

POI acknowledges that ovarian function is intermittent and unpredictable — not necessarily permanent. Approximately 5–10% of women with POI will have a spontaneous ovulation and occasional natural conception, even years after diagnosis. This is why the term "insufficiency" replaced "failure" — the ovaries are under-functioning but not necessarily completely failed.

The clinical distinction matters for fertility counselling: some women with POI do conceive naturally, particularly in the early stages.

Causes of POI

Autoimmune (most common identified cause, ~20%): The immune system produces antibodies against ovarian tissue. Often associated with other autoimmune conditions — thyroid disease (particularly autoimmune thyroiditis), type 1 diabetes, Addison's disease, rheumatoid arthritis. Thyroid and adrenal antibodies should be checked in all POI patients.

Genetic causes:

• Turner syndrome (45,X or mosaics) — most common genetic cause; often diagnosed in childhood but mild mosaics may present as POI in adulthood
• FMR1 premutation (fragile X gene premutation carriers) — a very important cause. Approximately 13–24% of women with POI carry an FMR1 premutation. This is critical because FMR1 premutation is an X-linked condition that can be passed to children — genetic counselling is essential.
• Other chromosomal abnormalities (deletions, translocations involving the X chromosome)

Iatrogenic (treatment-related):

• Chemotherapy — particularly alkylating agents (cyclophosphamide, busulfan, melphalan)
• Pelvic or total body radiotherapy
• Bilateral oophorectomy
• Repeated ovarian surgery

Infections: Mumps oophoritis (increasingly rare with vaccination). Some viral infections.

Idiopathic (no identified cause, ~50%): The majority of POI cases have no identifiable cause despite investigation.

How POI Is Diagnosed

Symptoms:

• Absent or infrequent periods (oligo/amenorrhoea)
• Hot flushes, night sweats (vasomotor symptoms)
• Vaginal dryness
• Reduced libido
• Mood changes, brain fog
• Some women have minimal or no symptoms, with diagnosis made incidentally during infertility investigation

Diagnostic criteria (ESHRE 2023):

• Age under 40
• Oligo/amenorrhoea for at least 4 months
• Elevated FSH on two occasions at least 4 weeks apart: FSH >25 IU/L
• Low estradiol

Additional investigations:

• AMH (typically very low or undetectable in POI)
• Pelvic ultrasound (low or absent antral follicles)
• Karyotype (to identify chromosomal cause)
• FMR1 gene analysis (fragile X premutation)
• Autoimmune screen: anti-TPO, adrenal antibodies, anti-ovarian antibodies (limited specificity)
• Bone mineral density (DEXA scan) — estrogen deficiency causes accelerated bone loss

Health Implications of POI Beyond Fertility

POI means prolonged estrogen deficiency. Untreated, this causes:

• Accelerated bone loss — risk of osteoporosis by age 50 if untreated
• Cardiovascular risk — early estrogen withdrawal increases cardiovascular disease risk
• Cognitive function — some evidence of accelerated cognitive decline
• Urogenital symptoms — vaginal atrophy, recurrent UTIs

HRT (hormone replacement therapy) is strongly recommended for all women with POI until the average age of natural menopause (~51 years) — both for symptom management and to protect bone and cardiovascular health. HRT use in POI is not the same as HRT after natural menopause and does not carry the same risk profile.

Fertility Options in POI

Natural conception: Approximately 5–10% of women with POI have a spontaneous pregnancy, particularly early in the course of the condition when occasional ovulation still occurs. Natural attempts are reasonable for a period, particularly if cycles are occasionally occurring.

Egg donation IVF: The most effective treatment for infertility in POI. A donor's eggs (from a woman typically aged 20–30) are fertilised and the resulting embryos transferred into the POI patient's uterus. The uterus in POI is normal and capable of carrying pregnancy — success is driven by donor egg quality, not the recipient's ovarian status.

Donor egg IVF success rates in POI: 40–55% live birth rate per transfer — comparable to donor egg IVF in any other patient group. The uterus of women with POI responds normally to estrogen preparation.

Egg/embryo freezing before cancer treatment: For women facing gonadotoxic treatment, emergency egg or embryo freezing before chemotherapy/radiotherapy is the most effective preservation strategy. ASRM and ESHRE recommend fertility counselling and preservation referral before any gonadotoxic treatment.

Experimental — ovarian tissue transplantation: Freezing and later transplanting ovarian cortex tissue (containing primordial follicles) has resulted in over 200 live births worldwide. Not yet standard, but available at specialist oncofertility centres.

Genetic Counselling Is Essential

Women with POI who carry an FMR1 premutation have a risk of passing this to their children — which can cause fragile X syndrome in grandchildren. Genetic counselling before any fertility treatment is strongly recommended for all POI patients, particularly those using their own eggs.

Reference: ESHRE Guideline — Premature Ovarian Insufficiency, 2024. ASRM Practice Committee — Evaluation and Management of POI, 2023.